DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervo ...
FDA Breakthrough Designation -- CardiAMP Cell Therapy for ischemic heart failure holds FDA breakthrough status and is ...
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and stud ...
The FDAs new QMSR quietly created a harmonized quality framework between the U.S. and Latin America. With high recruitment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results